Literature DB >> 17249650

Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug.

Irene G Boutselis1, Xiao Yu, Zhong-Yin Zhang, Richard F Borch.   

Abstract

Our laboratory recently reported the development of novel prodrug chemistry for the intracellular delivery of phosphotyrosine mimetics. This chemistry has now been adapted for the synthesis of a prodrug that delivers the nonhydrolyzable difluoromethylphosphonate moiety intracellularly. Activation of the prodrug generates a difluoromethylphosphonamidate anion that undergoes subsequent cyclization and hydrolysis with a t1/2 = 44 min. A highly potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with a nanomolar Ki has been reported, but this bis(difluoromethylphosphonate) lacks potential utility due to its exceedingly low membrane permeability at physiological pH. A prodrug of this inhibitor has been synthesized and evaluated in a cell-based assay. The prodrug exhibits nanomolar PTP1B inhibitory activity in this assay, confirming the efficacy of intracellular phosphonate delivery using this prodrug approach.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17249650     DOI: 10.1021/jm061146x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Synthesis of a phosphoserine mimetic prodrug with potent 14-3-3 protein inhibitory activity.

Authors:  Allison Arrendale; Keunho Kim; Jun Young Choi; Wei Li; Robert L Geahlen; Richard F Borch
Journal:  Chem Biol       Date:  2012-06-22

Review 2.  Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.

Authors:  Lakshmi Reddy Bollu; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

Review 3.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

4.  Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK.

Authors:  Rong Huang; Hyunju Oh; Allison Arrendale; Victoria A Martin; Jacob Galan; Eric J Workman; Jane R Stout; Claire E Walczak; W Andy Tao; Richard F Borch; Robert L Geahlen
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

5.  Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form.

Authors:  Wen-Jian Qian; Terrence R Burke
Journal:  Amino Acids       Date:  2013-08-02       Impact factor: 3.520

Review 6.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 7.  Small molecule tools for functional interrogation of protein tyrosine phosphatases.

Authors:  Rongjun He; Li-Fan Zeng; Yantao He; Sheng Zhang; Zhong-Yin Zhang
Journal:  FEBS J       Date:  2012-08-16       Impact factor: 5.542

Review 8.  Signalling by protein phosphatases and drug development: a systems-centred view.

Authors:  Lan K Nguyen; David Matallanas; David R Croucher; Alexander von Kriegsheim; Boris N Kholodenko
Journal:  FEBS J       Date:  2012-03-14       Impact factor: 5.542

Review 9.  Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.

Authors:  Lutz Tautz; Yotis A Senis; Cécile Oury; Souad Rahmouni
Journal:  Bioorg Med Chem       Date:  2015-04-04       Impact factor: 3.641

10.  Efficient delivery of cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine.

Authors:  Amir Nasrolahi Shirazi; Rakesh Kumar Tiwari; Donghoon Oh; Antara Banerjee; Arpita Yadav; Keykavous Parang
Journal:  Mol Pharm       Date:  2013-04-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.